A new multicenter study that includes researchers at Washington University School of Medicine in St. Louis, the Centers for Disease Control and Prevention (CDC), and Vanderbilt University Medical Center shows that transplant recipients who receive three doses of COVID-19 mRNA vaccine have greater protection than that provided with two doses.
Trailblazer Victoria Fraser, MD, head of the Department of Medicine, the medical school’s largest department, advocates for equity in academic medicine and addresses structural barriers that limit the careers of women and members of other underrepresented groups.
Studying mice, Washington University School of Medicine researchers have discovered that roseolovirus can trigger autoimmunity in a previously unknown way: by disrupting the process by which immune cells learn to avoid targeting their own body’s cells and tissues.
Antibiotics provide no benefit in preventing future recurrent wheezing in babies hospitalized with respiratory syncytial virus (RSV), according to a new study led by Washington University School of Medicine researchers.
Antibodies elicited by COVID-19 vaccination become steadily more powerful for at least six months after vaccination, according to a study by researchers at Washington University School of Medicine that involved the Pfizer-BioNTech COVID-19 vaccine.
Health-care workers at the Washington University School of Medicine have contributed greatly to regional and world health during the pandemic, and we owe them so much appreciation.
Medical trailblazer Victoria Fraser, MD, focuses on creating equity in academic medicine.
Researchers at Washington University School of Medicine have shown, in mice, that a new class of compounds they developed can improve several aspects of metabolic syndrome. Such conditions often lead to cardiovascular disease, the leading cause of death worldwide.
Five researchers from the School of Medicine and one from the McKelvey School of Engineering have been named senior members of the National Academy of Inventors.
Washington University School of Medicine is participating in a nationwide phase 2 clinical trial to evaluate whether an investigational omicron-specific booster of the Moderna COVID-19 vaccine is safe and capable of eliciting a strong immune response.